NEW! CKB CORE users will be exposed to more gene content on a quarterly rotating basis. This month we highlight ARID1A and will return EGFR and PIK3CA later in 2019. These genes are always accessible in CKB BOOSTckbhome.jax.org
Vitrakvi (larotrectinib) approved regardless of tumor type for NTRK fusions, except with acquired resistance mutations! Need a list of resistance mutations? Visit ckbhome.jax.org and sign-up for CKB BOOST.